resultFull

BRAZIL-HEALTH-VIRUS-DENGUE

A worker prepares a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A health worker prepares to vaccinates a child against Dengue at a health center in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

PUBLIC TRANSIT IN NEW YORK

Passengers on an NYCTA M79 SBS bus traveling crosstown in New York on Wednesday, February 28, 2024. (Â Richard B. Levine) Photo via Newscom (KEYSTONE/NEWSCOM/Richard B. Levine)

ANTIBODIES ATTACKING VIRUS PARTICLE, ILLUSTRATION

Illustration of a virus particle (round) surrounded by antibody, or immunoglobulin, molecules. The y-shaped antibody molecules have two arms that can bind to specific antigens, for instance viral proteins. In doing this they mark the antigen for destruction by phagocytes, white blood cells that ingest and destroy foreign bodies. Antibodies can also kill some pathogens directly and can neutralise toxins. (KEYSTONE/SCIENCE PHOTO LIBRARY/KEITH CHAMBERS)

ANTIBODIES ATTACKING VIRUS PARTICLES, ILLUSTRATION

Illustration of virus particles (round) surrounded by antibody, or immunoglobulin, molecules. The y-shaped antibody molecules have two arms that can bind to specific antigens, for instance viral proteins. In doing this they mark the antigen for destruction by phagocytes, white blood cells that ingest and destroy foreign bodies. Antibodies can also kill some pathogens directly and can neutralise toxins. (KEYSTONE/SCIENCE PHOTO LIBRARY/KEITH CHAMBERS)

ANTIBODIES ATTACKING VIRUS PARTICLE, ILLUSTRATION

Illustration of a virus particle (round) surrounded by antibody, or immunoglobulin, molecules. The y-shaped antibody molecules have two arms that can bind to specific antigens, for instance viral proteins. In doing this they mark the antigen for destruction by phagocytes, white blood cells that ingest and destroy foreign bodies. Antibodies can also kill some pathogens directly and can neutralise toxins. (KEYSTONE/SCIENCE PHOTO LIBRARY/KEITH CHAMBERS)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff works inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) at Serum Institute of India (SII), speaks during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, staff monitor control panels inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff inspects vials of the R21 Malaria vaccine after its filling at the Serum Institute of India (SII) - the largest vaccine manufacturer in the world at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff arranges boxes of vials of the R21 Malaria Vaccine inside the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff prepares to manually check vials after disinfecting his protective gear inside the filling unit of the R21 Malaria Vaccine inside the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, vials of the R21 Malaria Vaccine are seen at the packing section of the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff inspects a vial of the R21 Malaria Vaccine at the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff monitors a control panel inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff packs vials of the R21 Malaria Vaccine at the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, the Serum Institute of India (SII) logo is seen at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff works inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff inspects a vial of the R21 Malaria Vaccine at the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India (SII), poses for pictures during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India (SII), poses for pictures during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India (SII), poses for pictures during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, motorists ride past a truck of Serum Institute of India (SII) - the largest vaccine manufacturer in the world in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India (SII), speaks during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff monitors a control panel inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff works inside the filling unit of the R21 Malaria Vaccine inside the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a pedestrian walks past the gate of the Serum Institute of India (SII) - the largest vaccine manufacturer in the world in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla (L), Chief Executive Officer (CEO) of Serum Institute of India (SII) speaks with Umesh Shaligram, research and development director, at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, staff monitor the production of vials of the R21 Malaria vaccine at the Serum Institute of India (SII) - the largest vaccine manufacturer in the world at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India (SII), poses for pictures during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff labels a box of vials of the R21 Malaria Vaccine inside the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India (SII), speaks during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India (SII), poses for pictures during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, staff work inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff inspects vials of the R21 Malaria Vaccine at the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

PERU-HEALTH-VIRUS-DENGUE

Brigaders of the Peruvian Health Ministry inspect a mosquito at the populous district of El Agustino in Lima, on February 27, 2024. Starting Tuesday, the Peruvian government will declare a state of health emergency in 20 of its 25 regions due to a strong outbreak of dengue, the chief of staff reported last Monday. (Photo by Cris BOURONCLE / AFP) (KEYSTONE/AFP/CRIS BOURONCLE)

PERU-HEALTH-VIRUS-DENGUE

A brigadier of the Peruvian Health Ministry inspects a mosquito at the populous district of El Agustino in Lima, on February 27, 2024. Starting Tuesday, the Peruvian government will declare a state of health emergency in 20 of its 25 regions due to a strong outbreak of dengue, the chief of staff reported last Monday. (Photo by Cris BOURONCLE / AFP) (KEYSTONE/AFP/CRIS BOURONCLE)

PERU-HEALTH-VIRUS-DENGUE

A medical technician, brigadier of a Peruvian Ministry of Health squad visiting residents at the populous district of El Agustino, inspects larvae of the Aedes aegypti mosquito during a house-to-house visit to instruct people on how to avoid and the dangers of Dengue, in Lima on February 27, 2024. Starting Tuesday, the Peruvian government will declare a state of health emergency in 20 of its 25 regions due to a strong outbreak of dengue, the chief of staff reported last Monday. (Photo by Cris BOURONCLE / AFP) (KEYSTONE/AFP/CRIS BOURONCLE)

PERU-HEALTH-VIRUS-DENGUE

A medical technician, brigadier of a Peruvian Ministry of Health squad visiting residents at the populous district of El Agustino, inspects larvae of the Aedes aegypti mosquito during a house-to-house visit to instruct people on how to avoid and the dangers of Dengue, in Lima on February 27, 2024. Starting Tuesday, the Peruvian government will declare a state of health emergency in 20 of its 25 regions due to a strong outbreak of dengue, the chief of staff reported last Monday. (Photo by Cris BOURONCLE / AFP) (KEYSTONE/AFP/CRIS BOURONCLE)

PERU-HEALTH-VIRUS-DENGUE

An aerial view of the populous district of El Agustino, where brigades of the Peruvian Ministry of Health are instructing residents on how to avoid and the dangers of Dengue, in Lima on February 27, 2024. Starting Tuesday, the Peruvian government will declare a state of health emergency in 20 of its 25 regions due to a strong outbreak of dengue, the chief of staff reported last Monday. (Photo by Cris BOURONCLE / AFP) (KEYSTONE/AFP/CRIS BOURONCLE)

RESPIRATORY SYNCYTIAL VIRUS, SEM

Respiratory Syncytial Virus A (RSV A). Scanning electron micrograph (SEM) of a HEp2/HeLa cell (Human epithelial cell) infected with RSV A (Strain Long) showing long filamentous enveloped particles emerging from the plasma membrane. Respiratory syncytial virus is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious. Infants and older adults are more likely to develop bronchiolitis and pneumonia requiring hospitalization. Magnification: x3200 when printed 10 centimetres wide. Specimen courtesy of Virology Research Services Ltd (Scott Lawrence). (KEYSTONE/SCIENCE PHOTO LIBRARY/STEVE GSCHMEISSNER)

RESPIRATORY SYNCYTIAL VIRUS, SEM

Respiratory Syncytial Virus A (RSV A). Scanning electron micrograph (SEM) of a HEp2/HeLa cell (Human epithelial cell) infected with RSV A (Strain Long) showing long filamentous enveloped particles emerging from the plasma membrane. Respiratory syncytial virus is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious. Infants and older adults are more likely to develop bronchiolitis and pneumonia requiring hospitalization. Magnification: x3200 when printed 10 centimetres wide. Specimen courtesy of Virology Research Services Ltd (Scott Lawrence). (KEYSTONE/SCIENCE PHOTO LIBRARY/STEVE GSCHMEISSNER)

RESPIRATORY SYNCYTIAL VIRUS, SEM

Respiratory Syncytial Virus A (RSV A). Scanning electron micrograph (SEM) of a HEp2/HeLa cell (Human epithelial cell) infected with RSV A (Strain Long) showing long filamentous enveloped particles emerging from the plasma membrane. Respiratory syncytial virus is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious. Infants and older adults are more likely to develop bronchiolitis and pneumonia requiring hospitalization. Magnification: x3200 when printed 10 centimetres wide. Specimen courtesy of Virology Research Services Ltd (Scott Lawrence). (KEYSTONE/SCIENCE PHOTO LIBRARY/STEVE GSCHMEISSNER)

RESPIRATORY SYNCYTIAL VIRUS, ILLUSTRATION

Illustration of respiratory syncytial virus (RSV) particles. RSV causes infections in the lungs and respiratory tract. It is very common in children, but it can also affect adults. The symptoms are usually mild, self-resolving and resemble those of the common cold. (KEYSTONE/SCIENCE PHOTO LIBRARY/NIAID)

MPOX VIRUS PARTICLES, TEM

Coloured transmission electron micrograph (TEM) of mpox (previously monkeypox) virus particles (red) within an infected cell (blue). In humans mpox infection causes fever, fatigue, body aches, swollen glands and a rash of fluid-filled blisters. Transmission can occur through direct contact with infectious skin or other lesions, bites or scratches from infected animals, or indirectly through contact with contaminated objects. The mpox virus was first discovered in 1958 in two outbreaks of a pox-like disease among colonies of research monkeys, though small mammals such as rodents are believed to be the natural hosts. The first human case was recorded in 1970 in the Democratic Republic of the Congo, and it is endemic in central and western Africa. Most people recover from mpox infection within 2-4 weeks, and a vaccine is available. (KEYSTONE/SCIENCE PHOTO LIBRARY/NIAID)

MPOX VIRUS PARTICLES, TEM

Coloured transmission electron micrograph (TEM) of mpox (previously monkeypox) virus particles (orange) within an infected cell (yellow). In humans mpox infection causes fever, fatigue, body aches, swollen glands and a rash of fluid-filled blisters. Transmission can occur through direct contact with infectious skin or other lesions, bites or scratches from infected animals, or indirectly through contact with contaminated objects. The mpox virus was first discovered in 1958 in two outbreaks of a pox-like disease among colonies of research monkeys, though small mammals such as rodents are believed to be the natural hosts. The first human case was recorded in 1970 in the Democratic Republic of the Congo, and it is endemic in central and western Africa. Most people recover from mpox infection within 2-4 weeks, and a vaccine is available. (KEYSTONE/SCIENCE PHOTO LIBRARY/NIAID)

RESPIRATORY SYNCYTIAL VIRUS, ILLUSTRATION

Illustration of respiratory syncytial virus (RSV) particles. RSV causes infections in the lungs and respiratory tract. It is very common in children, but it can also affect adults. The symptoms are usually mild, self-resolving and resemble those of the common cold. (KEYSTONE/SCIENCE PHOTO LIBRARY/NATIONAL INSTITUTES OF HEALTH, NIAID)

RESPIRATORY SYNCYTIAL VIRUS, ILLUSTRATION

Illustration of respiratory syncytial virus (RSV) particles. RSV causes infections in the lungs and respiratory tract. It is very common in children, but it can also affect adults. The symptoms are usually mild, self-resolving and resemble those of the common cold. (KEYSTONE/SCIENCE PHOTO LIBRARY/NATIONAL INSTITUTES OF HEALTH)

MPOX VIRUS PARTICLES, TEM

Coloured transmission electron micrograph (TEM) of mpox (previously monkeypox) virus particles (blue) within an infected cell (pink). In humans mpox infection causes fever, fatigue, body aches, swollen glands and a rash of fluid-filled blisters. Transmission can occur through direct contact with infectious skin or other lesions, bites or scratches from infected animals, or indirectly through contact with contaminated objects. The mpox virus was first discovered in 1958 in two outbreaks of a pox-like disease among colonies of research monkeys, though small mammals such as rodents are believed to be the natural hosts. The first human case was recorded in 1970 in the Democratic Republic of the Congo, and it is endemic in central and western Africa. Most people recover from mpox infection within 2-4 weeks, and a vaccine is available. (KEYSTONE/SCIENCE PHOTO LIBRARY/NIAID)

HIV-1 VIRUS PARTICLES, TEM

Coloured transmission electron micrograph (TEM) of HIV-1 virus particles (orange) budding from the membrane of a T-cell white blood cell (green). Budding virus particles that have not yet separated from the cell appear as semi-circles. HIV (human immunodeficiency virus) infects helper T-cells, which are part of the body's immune system. HIV enters the cell and replicates, before destroying the cell as the new viruses emerge through its membrane. Eventually this severely weakens the immune system, causing AIDS (acquired immunodeficiency syndrome). (KEYSTONE/SCIENCE PHOTO LIBRARY/NATIONAL INSTITUTES OF HEALTHNIAID)

HIV-1 VIRUS PARTICLES, TEM

Coloured transmission electron micrograph (TEM) of HIV-1 virus particles (yellow/gold) budding from the membrane of a T-cell white blood cell (blue). Budding virus particles that have not yet separated from the cell appear as semi-circles. HIV (human immunodeficiency virus) infects helper T-cells, which are part of the body's immune system. HIV enters the cell and replicates, before destroying the cell as the new viruses emerge through its membrane. Eventually this severely weakens the immune system, causing AIDS (acquired immunodeficiency syndrome). (KEYSTONE/SCIENCE PHOTO LIBRARY/NATIONAL INSTITUTES OF HEALTH, NIAID)

HIV-1 VIRUS PARTICLES, TEM

Coloured transmission electron micrograph (TEM) of HIV-1 virus particles (red) budding from the membrane of a T-cell white blood cell (blue). Budding virus particles that have not yet separated from the cell appear as semi-circles. HIV (human immunodeficiency virus) infects helper T-cells, which are part of the body's immune system. HIV enters the cell and replicates, before destroying the cell as the new viruses emerge through its membrane. Eventually this severely weakens the immune system, causing AIDS (acquired immunodeficiency syndrome). (KEYSTONE/SCIENCE PHOTO LIBRARY/NATIONAL INSTITUTES OF HEALTH, NIAID)

HEPATITIS B VIRUS, ILLUSTRATION

Illustration of hepatitis B virus (HBV) particles. HBV causes the disease hepatitis B (hep B), which affects the liver. Hep B can cause acute symptoms lasting several weeks, from which most recover naturally, but chronic hep B can cause cirrhosis and liver cancer to develop over many years. There is no cure for chronic hep B, but vaccines exist which are offer near 100 percent protection from infection. (KEYSTONE/SCIENCE PHOTO LIBRARY/NATIONAL INSTITUTES OF HEALTH, NATIONAL INSTITUTES OF HEALTH)

HEPATITIS B VIRUS, ILLUSTRATION

Illustration of hepatitis B virus (HBV) particles. HBV causes the disease hepatitis B (hep B), which affects the liver. Hep B can cause acute symptoms lasting several weeks, from which most recover naturally, but chronic hep B can cause cirrhosis and liver cancer to develop over many years. There is no cure for chronic hep B, but vaccines exist which offer near 100 percent protection from infection. (KEYSTONE/SCIENCE PHOTO LIBRARY/NATIONAL INSTITUTES OF HEALTH, NIAID)

HEPATITIS B VIRUS, ILLUSTRATION

Illustration of a hepatitis B virus (HBV) particle. HBV causes the disease hepatitis B (hep b), which affects the liver. Hep B can cause acute symptoms lasting several weeks, from which most recover naturally, but chronic hep B can cause cirrhosis and liver cancer to develop over many years. There is no cure for chronic hep B, but vaccines exist which offer near 100 percent protection from infection. (KEYSTONE/SCIENCE PHOTO LIBRARY/NATIONAL INSTITUTES OF HEALTH, NIAID)

TOPSHOT-BRAZIL-HEALTH-VIRUS-DENGUE-FUMIGATION

TOPSHOT - A health worker fumigates against the Aedes aegypti mosquito, a vector of the dengue, Zika, and Chikungunya viruses in Contagem, metropolitan region of Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024, as the country faces a substantial increase in dengue fever cases. Brazil will begin a dengue immunization campaign in February following a surge in cases that has put the government on alert, officials said. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A dose of the Qdenga vaccine is pictured in a private laboratory in Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024. Brazil will begin a dengue immunization campaign in February following a surge in cases that has put the government on alert, officials said. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A dose of the Qdenga vaccine is pictured in a private laboratory in Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024. Brazil will begin a dengue immunization campaign in February following a surge in cases that has put the government on alert, officials said. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A dose of the Qdenga vaccine is pictured in a private laboratory in Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024. Brazil will begin a dengue immunization campaign in February following a surge in cases that has put the government on alert, officials said. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE-FUMIGATION

A health worker fumigates against the Aedes aegypti mosquito, a vector of the dengue, Zika, and Chikungunya viruses in Contagem, metropolitan region of Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024, as the country faces a substantial increase in dengue fever cases. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE-FUMIGATION

A health worker fumigates against the Aedes aegypti mosquito, a vector of the dengue, Zika, and Chikungunya viruses in Contagem, metropolitan region of Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024, as the country faces a substantial increase in dengue fever cases. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE-FUMIGATION

A health worker fumigates against the Aedes aegypti mosquito, a vector of the dengue, Zika, and Chikungunya viruses in Contagem, metropolitan region of Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024, as the country faces a substantial increase in dengue fever cases. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE-FUMIGATION

A health worker fumigates against the Aedes aegypti mosquito, a vector of the dengue, Zika, and Chikungunya viruses in Contagem, metropolitan region of Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024, as the country faces a substantial increase in dengue fever cases. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE-FUMIGATION

A health worker fumigates against the Aedes aegypti mosquito, a vector of the dengue, Zika, and Chikungunya viruses in Contagem, metropolitan region of Belo Horizonte, state of Minas Gerais, Brazil, on February 2, 2024, as the country faces a substantial increase in dengue fever cases. (Photo by DOUGLAS MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)